Our study proved the anticancer effect of KW-2478 on imatinib-sensitive and imatinib-resistant CML cells by inhibiting the chaperone function of HSP90α, weakening the BCR/ABL and MAPK signalling pathways and causing mitochondrial dysfunction to activate the caspase pathway. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.